Paragonix Technologies Inc.
2 Canal Park, Fifth Floor
58 articles with Paragonix Technologies Inc.
Paragonix Technologies, Inc., a leader in organ preservation technology and research, has announced the publication of a groundbreaking organ transplant study in the American Society for Artificial Internal Organs Journal.
Paragonix Launches Comprehensive Digital Platform for Real-Time Tracking of Donor Organs Destined for Transplantation
Paragonix Technologies, Inc., a leader in Advanced Organ Preservation technology, has announced the launch of its new VantagePoint™ Organ Tracking Technology to pioneer a new era of continuous oversight and real-time visibility for donor organs in transit.
Paragonix Technologies Celebrates Clinical Milestone of over 2,000 Organs Preserved and Transported for Transplantation
Paragonix Technologies, Inc. is announcing a major milestone of preserving over 2,000 donor organs, providing transplant centers Advanced Organ Preservation (AOPT) technology and a nationwide clinical support network.
Paragonix Technologies , the leading hypothermic organ preservation provider, announced today its expanded enrollment in its GUARDIAN series of clinical registries aimed at investigating the impact of organ preservation.
Paragonix Technologies Announces Expanded Adoption of their LIVERguard™ System at the 2022 American Transplant Congress
Paragonix Technologies, Inc., a leading organ preservation provider, announced expanded adoption of their LIVERguard Donor Liver Preservation System at the 2022 American Transplant Congress in Boston, Massachusetts.
Paragonix Technologies Presenting New Organ Preservation Research at the International Society of Heart and Lung Transplantation 2022 Annual Meeting
Paragonix Technologies, Inc., a leading organ preservation provider, is presenting new research on a variety of organ preservation, transportation and clinical data collection topics.
Paragonix Technologies LUNGguard ™ Used in Record Cross-Country Donor Lung Transplant Case.
Paragonix Announces First-in-Human use of LIVERguard™ Donor Liver Preservation System by Mayo Clinic
Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today the first-in-human clinical use of the only FDA cleared cold storage device for donor livers, the LIVERguard™ Donor Liver Preservation System by Mayo Clinic in Florida, one of the largest Liver Transplant Centers in the United States.
Paragonix Technologies, the leading provider of donor organ preservation and transport systems, announces the clinical and commercial launch of LIVERguard™ Donor Liver Preservation System in both the US and Europe, along with the launch of its clinical global registry, GUARDIAN-LIVER.
Paragonix Technologies Announces Global Registry for Pediatric Donor Heart Preservation; Enrolls First Patient
Paragonix Technologies, Inc. announces that the University of Florida Health is the first to enroll a pediatric heart transplant recipient into the Company’s post-market registry, the Global Utilization And Registry Database for Improved preservAtion of donor HEARTs Pediatric Registry.
Paragonix Technologies Announces GUARDIAN-LUNG, the First Global Registry for Studying Donor Lung Preservation
Paragonix Technologies, Inc. today announces the launch of its clinical global registry, GUARDIAN-LUNG (Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs).
Paragonix Technologies , the leading hypothermic cardiothoracic organ preservation provider, announced today that Bill Edelman, Chief Executive Officer and Chairman of the Board, will present at in the 23 rd Annual Needham Virtual Growth Conference on January 11-15 th , 2021 in a series of virtual 1:1 meetings reviewing the company’s rapid int
Paragonix Technologies Receives Coveted International Design Award for Novel Organ Transportation System
Paragonix Technologies, Inc . today announced that its flagship product, Paragonix SherpaPak™ Cardiac Transport System (CTS), is the recipient of a prestigious international design award: the Red Dot Award . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200720005071/en/ Paragonix SherpaPak CTS is a 2020 Red Dot Award winner for product design
Paragonix Technologies Announces Utilization of Paragonix SherpaPak CTS in Complex Heart Transplant Study
Paragonix Technologies, Inc . announced the presentation of new clinical data at the American Transplant Congress (ATC) on the successful use of the Paragonix SherpaPak™ Cardiac Transport System (CTS) for high-risk donor hearts at the Medical University of Vienna - Allgemeines Krankenhaus Wien
Paragonix Technologies Announces Appointment of Alexander K. Arrow, MD, CFA to the Board of Directors
June 22, 2020 12:39 UTC Paragonix expands Boards to support rapid commercial growth in the heart transplant market CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Paragonix Technologies, Inc . a commercial stage company and leader in organ preservation and transport technology, today announced that Alexander K. Arrow, MD, CFA has joined its Board of Directors. Dr. Arrow is a medical technology executive with 24 years of experience in management and finance roles at small and me
Paragonix Technologies designs, produces, and sells organ preservation and transport devices that safeguard organs during the journey between donor and recipient patients. Our award-winning devices mitigate risk in an otherwise high stakes environment.
Paragonix Technologies Announces Enrollment Milestone for its Global Registry for Donor Heart Preservation
The Paragonix GUARDIAN Registry has reached its 100th patient enrollment milestone
Paragonix Technologies, Inc., Announces AdventHealth’s Adoption of Paragonix SherpaPak™ Cardiac Transport System
Paragonix Technologies, Inc. today announced AdventHealth (Orlando, Florida) has adopted its Paragonix SherpaPak™ Cardiac Transport System (CTS) for the preservation of donor hearts for transplantation. A recent application of this innovative technology permit
Feb. 10, 2020 13:00 UTC LUNGguard safeguards lungs between donor and recipient patients CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Paragonix Technologies, Inc. today announced clearance of a Pre-Marketing Notification (510(k)) with the US Food and Drug Administration (FDA) for its Donor Lung Preservation System - LUNGguard 1,2 . The Paragonix LUNGguard Donor Lung Preservation System is intended to be used for the static hypothermic preservation of lungs during transportat
Paragonix Technologies, Inc., Announces First Successful Use of Paragonix SherpaPak™ Cardiac Transport System in Pediatric Transplant Recipients
Feb. 5, 2020 16:41 UTC Paragonix SherpaPak™ Cardiac Transport System is the only FDA-cleared and CE-marked device that safeguards hearts between donor and recipient patients